• Users Online: 715
  • Print this page
  • Email this page

  Table of Contents  
Year : 2020  |  Volume : 11  |  Issue : 6  |  Page : 1007-1009  

Pirfenidone-induced dose-dependent phototoxicity – a distinct drug reaction

1 Department of Dermatology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India
2 Department of Pathology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India

Date of Submission26-Jan-2020
Date of Decision31-May-2020
Date of Acceptance24-Jun-2020
Date of Web Publication19-Sep-2020

Correspondence Address:
Reena Rai
Department of Dermatology, PSG Institute of Medical Sciences and Research, Coimbatore - 641 004, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/idoj.IDOJ_40_20

Rights and Permissions

How to cite this article:
Arunprasath P, Rai R, Venkataswamy C. Pirfenidone-induced dose-dependent phototoxicity – a distinct drug reaction. Indian Dermatol Online J 2020;11:1007-9

How to cite this URL:
Arunprasath P, Rai R, Venkataswamy C. Pirfenidone-induced dose-dependent phototoxicity – a distinct drug reaction. Indian Dermatol Online J [serial online] 2020 [cited 2021 Jun 25];11:1007-9. Available from: https://www.idoj.in/text.asp?2020/11/6/1007/295457


Pirfenidone is a novel drug with anti-fibrotic and anti-inflammatory properties used in the treatment of idiopathic lung fibrosis.[1] Herein, we report a case of pirfenidone-induced phototoxicity.

A 70-year-old male presented with hyperpigmented itchy skin lesions involving the face, forearms, and thighs for 10 days. His skin lesions were associated with photosensitivity, swelling of face, redness, and watering of eyes. History revealed that he was a recently diagnosed case of idiopathic pulmonary fibrosis and was started on treatment with pirfenidone 200mg two tablets thrice daily. Two months later the dose of pirfenidone was stepped-up to 200 mg three tablets thrice daily. One month after dose increment, the patient started developing itching and redness involving the photoexposed areas.

Cutaneous examination revealed hyperpigmentation with erythematous borders involving the face, “v”area of neck, forearms, dorsum of hands, upper back, thighs, and legs. There was a clear cut demarcation between the photoexposed and nonphotoexposed areas [Figure 1] and [Figure 2]. Examination of palms, soles, oral cavity, and genitalia did not reveal any abnormality. Routine hematological and biochemical investigations were within normal limits. Antinuclear antibody by immunofluorescence method was negative. Histopathological examination revealed epidermis exhibiting hyperkeratosis, parakeratosis, and large subcorneal clefting with extensive epidermal necrosis. There was also subepidermal blister formation containing fibrin and mixed inflammatory infiltrate. Dermis showed lichenoidinfiltrate composed of lymphocytes, plasma cells, occasional eosinophils, and neutrophils [Figure 3] and [Figure 4]. Naranjo algorithm showed a score of 6 with probable association of drug with the reaction. A diagnosis of pirfenidone-induced phototoxic drug reaction was entertained based on the distinct photodistributed skin lesions and extensive epidermal necrosis with dermal inflammatory infiltrate in histopthology.
Figure 1: Hyperpigmentation with erythematous borders involving the ”v”area of neck, forearms

Click here to view
Figure 2: Hyperpigmentation with erythematous borders involving thighs and legs

Click here to view
Figure 3: Epidermis with hyperkeratosis, parakeratosis, subcorneal clefting, extensive epidermal necrosis, and subepidermal blister formation with fibrin and mixed inflammatory infiltrate. Dermis showing inflammatory infiltrate composed of lymphocytes, plasma cells, occasional eosinophils, and neutrophils [H&E 100×]

Click here to view
Figure 4: Closer view showing keratinocyte necrosis and inflammatory cells in epidermis [H&E 400×]

Click here to view

Photosensitivity following drug intake occurs in two different patterns: phototoxicity and photoallergy. Phototoxicity is a nonimmunologic reaction following absorption of ultraviolet radiation by drug metabolites. On the contrary, photoallergic reaction is a cell-mediated immune reaction occurring in a sensitized host. Clinically phototoxic reaction mimics sunburn with sharp delineation to the sun exposed areas, whereas photoallergic reaction mimics eczema and it involves nonphotoexposed skin as well. Other patterns described in drug-induced photosensitivity include lichenoid skin lesions, pseudoporphyria, pellagra reaction, and photoonycholysis.[2]

Pirfenidone is an anti-fibrotic agent approved for treatment of idiopathic lung fibrosis. It inhibits transforming growth factor (TGF) -β stimulated collagen production by reducing fibroblast proliferation and production of fibrogenic mediators. Anti-inflammatory action is attributed to its inhibition of inflammatory cytokines like tumor necrosis factor-α, interleukin-1, and production of anti-inflammatory cytokine interleukin-10.[1]

In a study by Taniguchi et al. photosensitivity was the major adverse event observed in 51% of the patients in the high-dose group and 53% in low-dose group.[3] Apart from phototoxicity; pirfenidone-induced photoallergy and photoleucomelanoderma have been reported.[1],[4]

Seto et al. in their study assessed the photosafety of pirfenidone and concluded that there was production of singlet oxygen and superoxide radicals from drug metabolites of pirfenidone on exposure to sunlight pointing to its phototoxic potential. The study also showed that phototoxicity testing using high doses of pirfenidone in rats caused photosensitivity compared to low doses, pointing to the factthat phototoxic reaction parallels concentration of drug levels in skin.[5] Likewise in the present case skin lesions appeared after increment of the dose.

Diagnosis in drug induced photosensitivity can be established with histopathological examination, phototesting in case of phototoxic reaction, and photopatch testing in photoallergic reaction. Guillén et al. reported a similar case, where they conducted phototesting which showed a reduced minimal erythema dose and an aberrant response to ultraviolet A starting from 2 J/cm2.[6] In our case, histopathology revealed a picture consistent with phototoxic reaction, however phototesting was not done.

Treatment options include photoprotection, broad spectrum sunscreens, short course of steroids, and dose reduction or stopping of drug. With resolution of skin lesions reintroduction of the drug can be attempted with low doses. However in photoallergic reactions drug reintroduction should be avoided.[7],[8] The present case was treated with short course of steroids, sunscreens, and stopping of the drug with improvement of skin lesions. The present case is highlighted for the distinct side effect profile of a new therapeutic agent.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Kim HJ, Seo JW, Kim TH, Choi SH, Song KH, Kim KH. Pirfenidone-induced photosensitivity in a patient with idiopathic pulmonary fibrosis. Ann Dermatol 2018;30;614-6.  Back to cited text no. 1
Pandhi D. Phototoxic and photoallergic drug reactions. In: Gupta LK, Martin AM, editors. IADVL's textbook on cutaneous adverse drug reactions-A comprehensive guide. 1st edition. India: Bhalani Publishing House; 2018.p. 140-8.  Back to cited text no. 2
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.  Back to cited text no. 3
Tsuruta A, Washio K, Fukunaga A, Nishigori C. Pirfenidone induced photoleukomelanoderma in a patient with idiopathic pulmonary fibrosis. J Dermatol 2016;43:207-9.  Back to cited text no. 4
Seto Y, Inoue R, Kato M, Yamada S, Onoue S. Photosafety assessments on pirfenidone: Photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B 2013;120:44-51.  Back to cited text no. 5
Guillén BF, Giácaman MM, Oñate CV, Tapial JM, Bel PH, Ferriols AP. Pirfenidone-induced photosensitivity confirmed by pathological phototest. Photodiagnosis Photodyn Ther 2019;25:103-5.  Back to cited text no. 6
Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, et al. Pirfenidone in idiopathic pulmonary fibrosis: Expert panel discussion on the management of drug-related adverse events. Adv Ther 2014;31:375-91.  Back to cited text no. 7
Gaikwad RP, Mukherjee SS. Pirfenidone induced phototoxic reaction in an elderly man. Indian J Dermatol Venereol Leprol 2016;82:101-3.  Back to cited text no. 8
[PUBMED]  [Full text]  


  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 1], [Figure 2], [Figure 3], [Figure 4]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Article Figures

 Article Access Statistics
    PDF Downloaded33    
    Comments [Add]    

Recommend this journal